Skip to content

Study · Ex vivo tissue · mouse · 1992

4 results

Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases.

Tatro JB, Wen Z, Entwistle ML, Atkins MB, Smith TJ, Reichlin S, Murphy JR

Cancer research1 May 1992Cited by 44 (Europe PMC)

PMID1314697 (opens in a new tab)PepBankPUB-01314697
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In mouse melanoma tissue sections, NDP-MSH inhibited 125I-NDP-MSH binding with a half-maximal concentration of 0.63 nM.

    In plain wordsIn lab tests on mouse melanoma tissue, NDP-MSH blocked labelled NDP-MSH binding at 0.63 nM.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableHalf-maximal concentration for inhibition of 125I-NDP-MSH binding, mouse melanoma
    Study

    mousen: not reported in source

    melanoma metastasis tissue sections
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Measurements

    Half-maximal concentration
    0.63 nM
    mouse melanoma tissue

    Source sentences

    Summary
    Half-maximal peptide concentrations for inhibition of 125I-NDP-MSH binding to mouse melanoma tissue sections were: NDP-MSH, 0.63 nM
    2 context sentences
    Summary · context
    In the present study, binding of DAB389-MSH to melanotropin receptors in biopsy specimens of human and mouse melanoma metastases was assessed by measuring its ability to inhibit binding of a radiolabeled, superpotent analogue of alpha-MSH (125I-[Nle4,D-Phe7]-alpha-MSH; 125I-NDP-MSH) and comparing it…
    Summary · context
    Radioligand binding to tissue sections in vitro was localized and quantified by autoradiography and image analysis.
  2. 02LabEx vivo tissueActivity measurement

    In human melanoma metastasis tissue, NDP-MSH inhibited 125I-NDP-MSH binding with a half-maximal concentration of 1.80 nM.

    In plain wordsIn lab tests on human melanoma tissue, NDP-MSH blocked labelled NDP-MSH binding at 1.80 nM.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableHalf-maximal concentration for inhibition of 125I-NDP-MSH binding, human melanoma
    Study

    humann: not reported in source

    melanoma metastasis tissue sections
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Measurements

    Half-maximal concentration
    1.8 nM
    human melanoma tissue

    Source sentences

    Summary
    In human melanoma tissues, the respective half-maximal peptide concentrations for inhibition of 125I-NDP-MSH binding to mouse melanoma tissue sections were: NDP-MSH, 1.80 nM
    2 context sentences
    Summary · context
    In the present study, binding of DAB389-MSH to melanotropin receptors in biopsy specimens of human and mouse melanoma metastases was assessed by measuring its ability to inhibit binding of a radiolabeled, superpotent analogue of alpha-MSH (125I-[Nle4,D-Phe7]-alpha-MSH; 125I-NDP-MSH) and comparing it…
    Summary · context
    Radioligand binding to tissue sections in vitro was localized and quantified by autoradiography and image analysis.

Studies that did not test the peptide alone2

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 03LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement

    In mouse melanoma tissue and in melanoma metastases of three patients, the fusion protein DAB389-MSH inhibited binding of 125I-NDP-MSH.

    In plain wordsIn lab tests on mouse and human melanoma tissue, a toxin fused to alpha-MSH blocked the binding of labelled NDP-MSH.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseDAB389-MSH inhibition of 125I-NDP-MSH binding
    Study

    human, mousen: not reported in source

    melanoma metastasis tissue sections
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    DAB389-MSH inhibited binding of 125I-NDP-MSH to experimental murine B16-F1C23 melanoma metastasis tissue and to melanoma metastases of three patients.
    2 context sentences
    Summary · context
    In the present study, binding of DAB389-MSH to melanotropin receptors in biopsy specimens of human and mouse melanoma metastases was assessed by measuring its ability to inhibit binding of a radiolabeled, superpotent analogue of alpha-MSH (125I-[Nle4,D-Phe7]-alpha-MSH; 125I-NDP-MSH) and comparing it…
    Summary · context
    Radioligand binding to tissue sections in vitro was localized and quantified by autoradiography and image analysis.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 04LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement

    In mouse and human melanoma tissue, DAB389-MSH showed parallel concentration-response curves and comparable maximal inhibition of 125I-NDP-MSH binding to NDP-MSH and alpha-MSH.

    In plain wordsIn lab tests on melanoma tissue, a toxin fused to alpha-MSH blocked labelled NDP-MSH binding in a similar way to NDP-MSH and alpha-MSH.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableDAB389-MSH concentration-response compared with NDP-MSH and alpha-MSH
    Study

    human, mousen: not reported in source

    melanoma metastasis tissue sections
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    In both mouse and human melanoma tissues, concentration-response relationships for DAB389-MSH-mediated inhibition of 125I-NDP-MSH binding were parallel, and its maximal effects were comparable in magnitude, to those of NDP-MSH and alpha-MSH.
    2 context sentences
    Summary · context
    In the present study, binding of DAB389-MSH to melanotropin receptors in biopsy specimens of human and mouse melanoma metastases was assessed by measuring its ability to inhibit binding of a radiolabeled, superpotent analogue of alpha-MSH (125I-[Nle4,D-Phe7]-alpha-MSH; 125I-NDP-MSH) and comparing it…
    Summary · context
    Radioligand binding to tissue sections in vitro was localized and quantified by autoradiography and image analysis.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.